Timo Risch

Timo Risch

Auto-generated profile, based on publicly available information

Timo Risch

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Saarland University Department of Pharmacy, Saarbrücken, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
TRTill Reinhardt
Till Reinhardt
YHYassmine El Harraoui
Yassmine El Harraoui
ARAlex Rothemann
Alex Rothemann
AJAdrian T. Jauch
Adrian T. Jauch
SMSigrid Müller-Deubert
Sigrid Müller-Deubert
SSStephan A. Sieber
Stephan A. Sieber
Fluoroquinolones (FQs) are an important class of potent broad‐spectrum antibiotics. However, their general use is more and more limited by adverse side effects. While general mechanisms for the fluoroquinolone‐associated disability (FQAD) have been identified, the underlying molecular targets of toxicity remain elusive. In this study, focusing on the most commonly prescribed FQs Ciprofloxacin and Levofloxacin, whole proteome analyses revealed prominent mitochondrial dysfunction in human cells, specifically of the complexes I and IV of the electron transport chain (ETC). Furthermore, global untargeted chemo‐proteomic methodologies such as photo‐affinity profiling with FQ‐derived probes, as well as derivatization‐free thermal proteome profiling, were applied to elucidate human protein off‐targets of FQs in living cells. Accordingly, the interactions of FQs with mitochondrial AIFM1 and IDH2 have been identified and biochemically validated for their contribution to mitochondrial dysfunction. Of note, the FQ induced ETC dysfunction via AIFM1 activates the reverse carboxylation pathway of IDH2 for rescue, however, its simultaneous inhibition further enhances mitochondrial toxicity. This off‐target discovery study provides unique insights into FQ toxicity enabling the utilization of identified molecular principles for the design of a safer FQ generation.

21 March 2024 in Journal of the American Chemical Society
Verified
Journal Article
Open access
SASebastian Adam
Sebastian Adam
FFFranziska Fries
Franziska Fries
ATAlexander von Tesmar
Alexander von Tesmar
SRSari Rasheed
Sari Rasheed
SDSelina Deckarm
Selina Deckarm
RMRolf Müller
Rolf Müller
The rapid development of antibiotic resistance, especially among difficult-to-treat Gram-negative bacteria, is recognized as a serious and urgent threat to public health. The detection and characterization of novel resistance mechanisms are essential to better predict the spread and evolution of antibiotic resistance. Corramycin is a novel and modified peptidic antibiotic with activity against several Gram-negative pathogens. We demonstrate that the kinase ComG, part of the corramycin biosynthetic gene cluster, phosphorylates and thereby inactivates corramycin, leading to the resistance of the host. Remarkably, we found that the closest structural homologues of ComG are aminoglycoside phosphotransferases; however, ComG shows no activity toward this class of antibiotics. The crystal structure of ComG in complex with corramycin reveals that corramycin adopts a β-hairpin-like structure and allowed us to define the changes leading to a switch in substrate from sugar to peptide. Bioinformatic analyses suggest a limited occurrence of ComG-like proteins, which along with the absence of cross-resistance to clinically used drugs positions corramycin as an attractive antibiotic for further development.

5 November 2024 in npj Antimicrobials and Resistance
Verified
Journal Article
Open access
PDF file
TRTimo Risch
Timo Risch
DKDominik Kolling
Dominik Kolling
DMDietrich Mostert
Dietrich Mostert
TSTim Seedorf
Tim Seedorf
DHDominik Heimann
Dominik Heimann
RMRolf Müller
Rolf Müller
Antimicrobial resistance is one of the major health threats of the modern world. Thus, new structural classes of antimicrobial compounds are needed in order to overcome existing resistance. Cystobactamids represent one such new compound class that inhibit the well-established target bacterial type II topoisomerases while exhibiting superior antibacterial and resistance-breaking properties. Understanding potential mechanisms of emerging resistances is crucial in the development of novel antibiotics as they directly impact the future therapeutic application and market success. Therefore, the frequency and molecular basis of cystobactamid resistance in Escherichia coli was analyzed. High-level resistant E. coli mutants were selected and found to harbor single nucleotide polymorphisms in the promotor region of the ygiV gene, causing an upregulation of the respective protein. These stable mutations are contrary to what was observed as a resistance genotype in the structurally related albicidins, where ygiV gene amplifications were identified as causing resistance. Overexpression of YgiV in the mutants was additionally amplified upon cystobactamid exposition, showing further adaptation to this compound class under treatment. YgiV binds cystobactamids with high binding affinity, thereby preventing their interaction with the antimicrobial targets topoisomerase IV and DNA gyrase. In addition, we observed a substantial impact of YgiV on in vitro gyrase activity by leading to increased DNA cleavage and concurrent reduction in the efficacy of cystobactamids in inhibiting gyrase supercoiling activity. Furthermore, we identified co-upregulation of membrane-modifying proteins, such as EptC, and the transcriptional regulator QseB. This presumably contributes to the observed reduced motility and fimbrial protein expression in resistant mutants, resulting in a reduced expression of virulence factors and potentially pathogenicity, associated with ygiV promotor mutations.

5 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
RMRolf Müller
Rolf Müller
TRTimo Risch
Timo Risch
DKDominik Kolling
Dominik Kolling
DMDietrich Mostert
Dietrich Mostert
TSTim Seedorf
Tim Seedorf
SSStephan Sieber
Stephan Sieber
Antimicrobial resistance is one of the major health threats of the modern world. Thus, new structural classes of antimicrobial compounds are needed in order to overcome existing resistance. Cystobactamids as such a new compound class inhibit the well-established target bacterial type II topoisomerases while exhibiting superior antibacterial and resistance-breaking properties. Understanding potential mechanisms of emerging resistances is crucial in the development of novel antibiotics as they directly impact the future therapeutic application and market success. Therefore, the frequency and molecular basis of cystobactamid resistance in Escherichia coli was analyzed. High-level resistant E. coli mutants were selected and found to harbor single nucleotide polymorphisms in the promotor region of the ygiV gene, causing an upregulation of the respective protein. These stable mutations are contrary to what was observed as resistance genotype in the structurally related albicidins, where ygiV gene amplifications were identified causing resistance. Overexpression of YgiV in the mutants was additionally amplified upon cystobactamid exposition, showing further adaptation to this compound class under treatment. YgiV binds cystobactamids with high binding affinity, thereby preventing their interaction with the antimicrobial targets topoisomerase IV and DNA gyrase. Additionally, we observed stabilization of the gyrase cleavage complex by YgiV itself, suggesting a further protective effect against topoisomerase poisoning. Moreover, tested cystobactamid-resistant mutants show reduced motility and fimbrial protein expression, indicating an overall decreased virulence and potentially pathogenicity, associated with ygiV promotor mutations.

21 October 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
TRTill Reinhardt
Till Reinhardt
NBNina Bach
Nina Bach
ARAlex Rothemann
Alex Rothemann
AJAdrian T. Jauch
Adrian T. Jauch
YHYassmine El Harraoui
Yassmine El Harraoui
SSStephan A. Sieber
Stephan A. Sieber
Fluoroquinolones (FQs) are an important class of potent broad-spectrum antibiotics. However, their general use is more and more limited by adverse side effects. While general mechanisms for the fluoroquinolone-associated disability (FQAD) have been identified, the underlying molecular targets of toxicity remain elusive. In this study, focusing on the most commonly prescribed FQs Ciprofloxacin and Levofloxacin, whole proteome analyses revealed prominent mitochondrial dysfunction in human cells, specifically of the complexes I and IV of the electron transport chain (ETC). Furthermore, global untargeted chemo-proteomic methodologies such as photo-affinity profiling with FQ-derived probes, as well as derivatization-free thermal proteome profiling, were applied to elucidate human protein off-targets of FQs in living cells. Accordingly, the interactions of FQs with mitochondrial AIFM1 and IDH2 have been identified and biochemically validated for their contribution to mitochondrial dysfunction. Of note, the FQ induced ETC dysfunction via AIFM1 activates the reverse carboxylation pathway of IDH2, however, its simultaneous inhibition triggers mitochondrial toxicity. This off-target discovery study provides unique insights into FQ toxicity enabling the utilization of identified molecular principles for the design of a safer FQ generation.

17 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
TRTimo Risch
Timo Risch
BHBenedikt Hellwinkel
Benedikt Hellwinkel
DMDietrich Mostert
Dietrich Mostert
AKAndreas M. Kany
Andreas M. Kany
DSDanny Solga
Danny Solga
RMRolf Müller
Rolf Müller
Antimicrobial resistance (AMR) poses a fundamental global threat, necessitating new strategies for effective therapies. Cystobactamids (CYS), a class of antibacterial agents targeting bacterial gyrase and topoisomerase IV, represent a non-traditional chemical scaffold with broad-spectrum activity. For toxicological de-risking, we performed a comprehensive profiling on eukaryotic cells, focusing on cytotoxicity, genotoxicity, and mitochondrial toxicity, demonstrating cellular safety and superoxide scavenging properties. Studies in zebrafish embryos assessed developmental, cardiovascular, and hepatic toxicity, indicating a favorable in vivo safety profile. Metabolism studies revealed glucuronidation and amide bond hydrolysis as key pathways, whereby CYS metabolic stability substantially improved by cobicistat co-treatment. Affinity-based protein profiling identified the cholesterol- and HCV-receptor scavenger receptor class B member 1 (SCARB1) as a primary eukaryotic off-target protein, with cystobactamids shown to inhibit SCARB1’s function, preventing hepatitis C virus pseudoparticle entry into cells. These findings suggest a high therapeutic potential for cystobactamids and highlight SCARB1 as a primary eukaryotic target.